PEMANTAUAN TERAPI PASIEN PENDERITA CKD DAN HIPERTENSI DI SALAH SATU RUMAH SAKIT DI BANDUNG
Abstrak
CKD (Chronic Kidney Disease) merupakan gangguan yang terjadi pada fungsi ginjal secara progresif dan bersifat ireversible karena ginjal tidak mampu mempertahankan keseimbangan dan metabolisme cairan serta elektrolit yang mengakibatkan terjadi uremia (retensi urin dan penumpukan nitrogen dalam darah). Hipertensi merupakan penyebab yang umum dari gagal ginjal karena terjadinya peningkatan tekanan pada kapiler glomerulus. Penggunaan obat hipertensi juga dapat menyebabkan terjadinya edema. Anemia merupakan salah satu komplikasi yang sangat umum pada penderita CKD. Hal tersebut terjadi akibat penurunan produksi eritropoetin endogen pada ginjal. Pelaksanaan PTO ini dilakukan di salah satu Rumah Sakit di Bandung dengan pasien CKD stage V. Pasien tersebut juga didiagnosa CKD dengan asidosis metabolik, dengan diagnosa tambahan anemia dan trombositopenia dengan riwayat sebelumnya adalah hipertensi. Pemantauan Terapi Obat dilakukan dengan memastikan penggunaan obat yang tepat dan menghindari kejadian yang tidak diinginkan.
Kata kunci: CKD, Hipertensi, PTO
Abstract
CKD (Chronic Kidney Disease) is a progressive and irreversible disorder that occurs in kidney function because the kidneys are unable to maintain fluid and electrolyte balance and metabolism, resulting in uremia (urinary retention and nitrogen accumulation in the blood). Hypertension is a common cause of kidney failure due to increased pressure in the glomerular capillaries. The use of hypertension drugs can also cause edema. Anemia is a very common complication in patients with CKD. This occurs due to decreased production of endogenous erythropoietin in the kidneys. The PTO was carried out at a hospital in Bandung with a stage V CKD patient. The patient was also diagnosed with CKD with metabolic acidosis, with additional diagnoses of anemia and thrombocytopenia with a previous history of hypertension. Drug Therapy Monitoring is done by ensuring the proper use of drugs and avoiding unwanted events.
Keywords:CKD, Hypertension, PTO
Teks Lengkap:
PDFReferensi
Ayu, K., Ermawardani, Y., & Permatasari, D. (2021). Pemantauan Terapi Obat Pada Pasien CKD (Chronic Kidney Disease), Anemia , Hipertensi di Rumah Sakit “ X .” Social Clinical Pharmacy Indonesia Journal, 6(1), 6–10.
Victor S. Ringoringo, V. F. A. (2021). Dan Chronic Kidney Disease Di Ruang Rawat Inap Flamboyan Rumah Sakit “ X ” Periode 1 April- 31 Mei. Social Clinical Pharmacy Indonesia Journal, 6(1), 21–25.
Alruqyab, W.S., Price, M.J., Paudyal, V., dan Cox, A.R. (2021). Drug-Related Problems in Hospitalised Patients with Chronic Kidney Disease: A Systematic Review. Drug Saf Oct;44(10):1041-1058.
Capelli, I., Cianciolo, G., Gasperoni, L., Zappulo, F., Tondolo, F., Cappucilli, M., dan Manna, G.L. (2019). Folic Acid and Vitamin B12 Administration in CKD, Why Not?. Nutrients.; 11(2): 383
Cozzolino, M., Mangano, M., Galassi, A., Ciceri, P., Messa, P., & Nigwekar, S. (2019). Vitamin K in Chronic Kidney Disease. Nutrients, 11(1).
Campbell, N. dan Hasinoff, B. 1991. Iron Supplements : a common cause of drug interaction. Br.J.Clin. Pharmac. 31: 251-255.
Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., dan Ellingrod, V. 2020. Pharmacotherapy : A Pathophysiologic Approach Eleventh Edition. New York : Mc Graw Hill.
Delacroix, S., Chokka, R.G., dan Worthley, G. (2014). Hypertension: Pathophysiology and Treatment. J Neurol Neurophysiol 5:6
Gallant, K., dan Spiegel, D. (2017). Calcium Balance in Chronic Kidney Disease. Curr Osteoporos Rep.; 15(3): 214–221
Garcia-Garcia, Guillermo et al. (2015). “Chronic kidney disease (CKD) in disadvantaged populations.” Clinical kidney journal vol. 8,1:(3-6. doi:10.1093/ckj/sfu124
Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, Hamza S, Speed J, Hall ME. (2012). Hypertension: physiology and pathophysiology. Compr Physiol ;2:2393–442.
Kusumawardani, L.A., Andrajati, R., dan Nusaibah, A. (2020). Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia. J Res Pharm Pract.; 9(3): 140–145
Kemenkes RI. (2009). Pedoman Pemantauan Terapi Obat. Jakarta: Departemen Kesehatan RI.
Kemenkes RI. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit.
KDIGO. (2012). (Kidney Disease: Improving Global Outcomes) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl.
KDIGO. (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Journal of The International Society of Nephrology. Vol. 1 Issue 1
Koppe, L., Cassani de Oliveira, M., & Fouque, D. (2019). Ketoacid Analogues Supplementation in Chronic Kidney Disease and Future Perspectives. Nutrients, 11(9), 2071.
Lexi Comp. (2009). Drug Information Handbook. Canada: Lexi comp.
Skoutakis, V.A., Acchiardo, S.R., Meyer, M.C., dan Hatch, F.E. (1975). Folic acid
DOI: https://doi.org/10.24198/farmaka.v20i2.39722
DOI (PDF): https://doi.org/10.24198/farmaka.v20i2.39722.g18181
Refbacks
- Saat ini tidak ada refbacks.
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved